Ascendis Pharma Ads (NQ: ASND )

136.31 USD -1.69 (-1.22%)

Streaming Delayed Price Updated: 10:08 AM EDT, Jun 18, 2021 Add to My Watchlist

Price and Volume

Volume	41,244
Open	137.80
Bid (Size)	135.62 (1)
Ask (Size)	136.56 (1)
Prev. Close	138.00
Today's Range	135.60 - 139.02
52wk Range	119.11 - 183.98
Shares Outstanding	53,750,386
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News

Ascendis Pharma A/S Announces Extension of U.S. Food and Drug Administration Review Period for TransCon™ hGH (Lonapegsomatropin) for Pediatric Growth Hormone Deficiency

June 11, 2021

Prescription Drug User Fee Act (PDUFA) goal date extended by three months for further review of submission to September 25, 2021

The first hormone replacement therapy for hypoparathyroidism in China obtains IND approval for Phase III clinical trial

June 03, 2021

Performance

YTD	-17.63%	-17.63%
1 Month	-1.31%	-1.31%
3 Month	-4.57%	-4.57%
6 Month	-21.62%	-21.62%
1 Year	-5.17%	-5.17%

More News

Ascendis Pharma A/S Invites the Public to Attend “A Story of Courage: Living with Hypoparathyroidism” in Support of World Hypopara Awareness Day on June 1, 2021

May 28, 2021

Ascendis Pharma A/S Reports First Quarter 2021 Financial Results

May 27, 2021

Ascendis Pharma A/S Announces First Quarter 2021 Financial Results and Business Update Conference Call on May 27

May 17, 2021

Ascendis Pharma A/S Announces Expansion of Global Clinical Reach for TransCon™ PTH with Filing of the Clinical Trial Notification for Phase 3 Clinical Trial in Adults with Hypoparathyroidism in Japan

May 12, 2021

Ascendis Pharma A/S Announces Preliminary 58-Week Results from Open-Label Extension of Phase 2 PaTH Forward Trial of TransCon PTH in Adult Hypoparathyroidism Demonstrated Durable Benefit and a Well-To

May 10, 2021

Ascendis Pharma A/S Announces Presentations for TransCon™ PTH at Upcoming Medical Conferences

May 06, 2021

Ascendis Pharma's TransCon hGH FDA Review Pushed Backed By Three Months

June 14, 2021

Ascendis Pharma A/S Announces Participation at the BofA Securities 2021 Virtual Health Care Conference

May 04, 2021

Ascendis Pharma A/S Announces Presentations for TransCon™ hGH at Upcoming Medical Conferences

April 21, 2021

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.